Skip to main content

Laurence Reid, Ph.D.

Board Member

KalVista Pharmaceuticals, Inc.

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Laurence Reid, Ph.D.

Laurence Reid, Ph.D. is recorded as Board Member at KalVista Pharmaceuticals, Inc.. KalVista Pharmaceuticals, Inc. reported in an 8-K filed June 11, 2026 that Laurence Reid, Ph.D. resigned as member of the Company's board of directors. KalVista Pharmaceuticals, Inc. reported in an 8-K filed November 26, 2024 that Laurence Reid, Ph.D. was appointed Class III Director, effective November 23, 2024.

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company's board of directors and all committees thereof”
KalVista Pharmaceuticals, Inc. Form 8-K, filed June 11, 2026 · Read the filing
“On November 23, 2024 upon the recommendation of the Nominating and Governance Committee of the Board of Directors (the "Board") of KalVista Pharmaceuticals (the "Company"), the Board approved the appointment of Laurence Reid, Ph.D. ("Dr. Reid") to the Board effective immediately, to serve until his successor is duly elected and qualified, or until his death, resignation or removal.”
KalVista Pharmaceuticals, Inc. Form 8-K, filed November 26, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • KalVista Pharmaceuticals, Inc.

    Board Member

    SEC 8-K

    Current

    2024-11-23–present

  • KalVista Pharmaceuticals, Inc.

    Board Member

    SEC 8-K

    2024-11-23–2026-06-11

Company network

Recorded roles and call appearances connecting this person to public companies.

KalVista Pharmaceuticals, Inc.

Current role

Board Member

2024-11-23–present

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.